1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67AA5C7B87F61DF57852579FB0069F91B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/crisis-management-assessing-risks-prioritizing-response-structure-leadership?opendocument
18
19opendocument
2054.227.157.163
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Business Operations » Supply Chain

Crisis Management & Business Continuity Excellence: Assessing Structure, Training and Risk for BioPharma Manufacturing and Supply Chain Operations

ID: 5204


Features:

21 Info Graphics

18 Data Graphics

100+ Metrics

11 Narratives

2 Best Practices


Pages/Slides: 47


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Crisis Management & Business Continuity Excellence: Assessing Structure, Training and Risk for BioPharma Manufacturing and Supply Chain Operations"


STUDY OVERVIEW

Crisis Management & Business Continuity have claimed urgent new attention in the global BioPharma and Medical Device sector. After witnessing devastating events -- such as Japan’s triple-punch disaster in 2011 (earthquake, tsunami and partial nuclear meltdown) that disrupted global supply chain and manufacturing plants in Japan -- many companies are anxiously revisiting their disaster recovery plans.

Best Practices, LLC conducted this study to assess how world-class companies optimize their Business Continuity preparations as well as respond when faced with major disasters or operating disruptions. More specifically, the research is designed to help participating companies develop an evidence-based understanding of how other companies plan, prevent, prepare and respond to threats to their supply chains and operations. The study includes benchmarks around structure and leadership of this function as well as different tactics surround emergency response.

KEY TOPICS

  • Structure & Leadership
  • Emergency Response: Building Capabilities to Respond Quickly & Effectively Throughout Your "Ecosystem"
  • Assessing Risks & Prioritizing Response

SAMPLE KEY METRICS
  • Steps taken to strengthen Enterprise Risk Management
  • Key functions where Business Continuity group reports
  • Structure of business continuity leadership group
  • Job title that leads Business Continuity function
  • Highest job title level to which Business Continuity function reports
  • Percentage of capital expense plan spend devoted to Business Continuity projects and investments
  • Frequency of emergency response training for key operations groups
  • Percentage of total operations staff undergoing response/crisis management training
  • Frequency of emergency response drills for ensuring successful emergency management and business continuity
  • Effectiveness of different improvement actions / programs to enhance business continuity and risk management readiness
  • Methods employed to stress test and inform business continuity plans
  • Approaches employed for staffing an emergency or disaster response
  • Effectiveness of different approaches for avoiding emergency outages and disasters
  • Effectiveness of various technology / software approaches that support business sustainability
  • Level of importance of different elements to business continuity / crisis management plan

SAMPLE KEY FINDING
  • Centralization/ Fast Response: Business continuity embraces centralized structures that support fast decision-making. However, disruptions occur in field & operations. Develop fast response capabilities throughout enterprise.
  • The Supply Chain Can Be Disrupted in Many Ways: Natural disasters are not the only threat to a company’s supply of medical products to the market and its customers. Disruptions range widely from parts to material purity to manufacturing. Small disruptions can disrupt or shut down supply chains.
METHODOLOGY

The research is based on the insights of 33 Business Continuity (BC) leaders from 29 national and global health care organizations. In addition, selected executives provided qualitative insights through deep-dive interviews and “lessons learned” observations.

Industries Profiled:
Biotech; Pharmaceutical; Medical; Manufacturing; Medical Device; Health Care; Diagnostic; Biopharmaceutical; Clinical Research; Laboratories; Consumer Products; Chemical


Companies Profiled:
Amgen; Alameda County Medical Center; Insight Adhesives Research; Siemens Medical; Nypro; GlaxoSmithKline; Abbott; UCB Pharma; Genzyme; Shire; Fibrogen; Terumo Corporation; Sanofi; Merck; Ipsen; Amylin; Lilly; Boehringer Ingelheim; Boston Scientific; Bayer Healthcare; Johnson & Johnson; Genentech; EMD Serono; Ben Venue Laboratories; Janssen; Smith & Nephew; Grifols; MedImmune


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.